secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001140361-23-039201
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma Q2 net loss $5.0M ($0.24/sh); cash $40M, Lincoln Park $50M financing
--------------------------------------------------------------------------------

- Cash and cash equivalents of $40.0M as of June 30, 2023; no debt; operations funded into 2025.
- License revenue of $3.7M in Q2 2023 vs $0 in prior-year period; net loss $5.0M vs $4.9M.
- Nyxol PDUFA date September 28, 2023; FDA approval would trigger a $10M milestone payment.
- End-of-Phase 2 meeting with FDA for oral APX3330 in diabetic retinopathy scheduled for Q4 2023.
- Entered common stock purchase agreement with Lincoln Park for up to $50M over 30 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123039201/0001140361-23-039201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123039201/brhc20057386_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-039201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer